The company in question is a direct-to-consumer skincare brand specializing in treatments for chronic skin conditions such as hyperpigmentation, melasma, and rosacea. This science-driven brand was launched in November 2024 and targets primarily women aged 45–65, with the United Kingdom as its main market. The brand has gained traction through proprietary clinical approaches like its Triple-Layer Pigmentation Technology. Notable products include the Dark Spot Corrector, Rosacea Corrector, and Melasma Corrector. Financially, the company demonstrates robust figures with an annual revenue of approximately €3.64 million and a net profit margin of about 14% after salaries. Bi-monthly recurring revenue stands at around $300,000. The market is well-distributed across major Western regions, predominantly in the UK but also in the US, Australia, and beyond. The organizational structure comprises roles in operations, marketing, customer service, and paid media, complemented by a registered trademark to safeguard brand assets. Using a Shopify-based model, the company employs various strategies for growth, including paid Meta acquisition and high-AOV bundle offerings. Future expansion includes subscription model intensification, Amazon FBA entry, scaling paid media, and influencer partnerships. There is potential for vertical growth into new areas like hair and nail care. The overall investment rationale is solid, with well-established financials and infrastructure primed for further scaling by tapping into untouched markets and expanding product lines.